Cannabidiol (CBD) and its analogs: a review of their effects on inflammation

Burstein, Sumner

doi:10.1016/j.bmc.2015.01.059

Cited by 458 publications

(389 citation statements)

References 65 publications

Supporting

Mentioning

364

Contrasting

Unclassified

Order By: Relevance

“…Cannabidiol, the major constituents of plant cannabis has shown anti-inflammatory properties in many organs (28). Cannabinoids decrease Th17 inflammatory autoimmune phenotype and modulate autoimmune cytokines by reducing expression of the pathogenic IL-17 and IL-6 cytokines, while raising the expression of the anti-inflammatory cytokine IL-10 (29).…”

Section: Discussionmentioning

confidence: 99%

Severity and outcomes of acute alcoholic pancreatitis in cannabis users

Goyal

Guerreso

Smith

et al. 2017

Transl. Gastroenterol. Hepatol.

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Severity and outcomes of acute alcoholic pancreatitis in cannabis users

Goyal

Guerreso

Smith

et al. 2017

Transl. Gastroenterol. Hepatol.

View full text Add to dashboard Cite

“…Experiments have demonstrated that low doses of CBD act as adenosine A2A receptor-and Peroxisome Proliferator Activated Receptor gamma (PPARg) agonist, and as G-protein coupled receptor 55 (GPR55) antagonist, decreasing the levels of inflammatory mediators such as TNF-alpha, IL-6 and IL-12, without acting directly on cyclooxygenase 1 or 2 (COX-1, COX-2 [15]. In addition, CBD is a very potent anti-oxidant, more protective than α-tocopherol or vitamin C [16].…”

Section: Discussionmentioning

confidence: 99%

Co-medication with Cannabidiol May Slow Down the Progression of Motor Neuron Disease: A Case Report

Nahler¹

2017

J Gen Pract

View full text Add to dashboard Cite

Amyotrophic lateral sclerosis (ALS, also called Charcot disease, Lou Gehrig disease), is a progressive, neurodegenerative disease caused by the degeneration of motor neurons in the brain and spinal cord. There is no cure. This report describes a case of motor neuron disease with typical weakness in one leg, one hand and the tongue. Despite of treatment with riluzole, symptoms progressed relatively fast. Therefore, the patient decided to take cannabidiol (CBD, 2 × 200 mg/day) as co-medication, which was started 8 weeks after riluzole, and increased to a daily dose of 2 × 300 mg. Within 6 weeks, the impaired function of the right hand and foot reversed almost completely and dysphagia partially. Improvement was maintained for about 10 weeks, when again a slow progression of dysarthria and dysphagia was observed. Eighteen months after onset, speech is almost completely lost, and dysphagia also progressed. However, symptoms of the limbs (weakness, fasciculation, atrophy) worsened much less. It is concluded, that Co-medication with CBD may be able to slow down the progression of some but not all symptoms of motor neuron disease.

show abstract

“…Anti-cancer effects have also been shown (Pisanti et al, 2017). Research involving CBD has burgeoned in recent years (Burstein, 2015;Zuardi, 2008). Concurrently, there has been a proliferation of synthetic CBD derivatives (for a list, see Morales, Reggio, & Jagerovic, 2017).…”

Section: ____________________________________________________________mentioning

confidence: 99%

Synthetic cannabinoids severely elevate amino transferase levels. Natural cannabidiol does not.

Cushing¹,

Joseph²

2018

View full text Add to dashboard Cite

Abstract:Cannabidiol (CBD) is a promising and well-studied medicinal compound found in cannabis. While CBD has a favorable safety profile, the deleterious health effects of synthetic cannabinoids are well documented. The human body is not equipped with the tools needed to catabolize synthetic cannabinoids. Among the enzymes recruited to removing them from the body are Alanine Amino Transferase (ALT) and Aspartate Amino Transferase (AST). The present article is broken into one naturalistic medical observation, and two studies. Each of these is concerned with the ALT and AST levels of patients exposed to cannabinoids. The medical observation is of four patients who mistakenly consumed a dangerous synthetic cannabinoid, JWH-018. Their ALT and AST levels were recorded once. The first experimental study is of six patients that consumed a synthetic CBD derivative, H4-CBD. ALT and AST levels were recorded over 22 weeks. The second experimental study is of 184 patients that consumed natural CBD. ALT and AST levels were recorded over 6 months. Taken together, these studies demonstrate clear differences between consumption of natural CBD, and two synthetic derivatives on ALT and AST levels.

show abstract

Cannabidiol (CBD) and its analogs: a review of their effects on inflammation

Cited by 458 publications

References 65 publications

Severity and outcomes of acute alcoholic pancreatitis in cannabis users

Severity and outcomes of acute alcoholic pancreatitis in cannabis users

Co-medication with Cannabidiol May Slow Down the Progression of Motor Neuron Disease: A Case Report

Synthetic cannabinoids severely elevate amino transferase levels. Natural cannabidiol does not.

Contact Info

Product

Resources

About